J&J’s HIV Therapy Etravirine Shown To Have Antiviral Activity In Phase III Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
Two Phase III trials found significantly more patients taking the non-nucleoside reverse transcriptase inhibitor reached undetectable viral load.
You may also be interested in...
J&J’s EPO Franchise Takes A Hit From Regulatory Scrutiny
Sales of the erythropoiesis-stimulating agent Procrit plunged 14 percent in the second quarter, causing J&J to revise sales expectations.
J&J’s EPO Franchise Takes A Hit From Regulatory Scrutiny
Sales of the erythropoiesis-stimulating agent Procrit plunged 14 percent in the second quarter, causing J&J to revise sales expectations.
J&J’s Prezista Approved For Treatment-Resistant HIV
The protease inhibitor – formerly known as TMC-114 – is to be co-administered with a low dose of ritonavir.